Belgium Strengthens Medical Device Oversight Through National Regulatory Authority

Belgium continues to play an important role in the European regulatory landscape for medical devices, with a strong focus on compliance, safety monitoring, and alignment with European regulatory frameworks. The country’s national regulator, the Federal Agency for Medicines and Health Products (FAMHP), oversees the regulation of medicines and medical devices placed on the Belgian market.

As the European Union continues to implement the European Union Medical Device Regulation (EU MDR) and the In Vitro Diagnostic Regulation (IVDR), Belgium has been actively strengthening its regulatory oversight to ensure that manufacturers comply with evolving requirements.

Belgium’s Role in the EU Regulatory Framework

Belgium operates within the broader European regulatory system governing medical technologies. Under the EU MDR and IVDR frameworks, manufacturers must demonstrate that their medical devices meet strict requirements for safety, quality, and performance before being placed on the market.

The FAMHP is responsible for enforcing these requirements at the national level, including supervising market activities, monitoring compliance, and coordinating with other European regulators.

This cooperation across the European regulatory network helps maintain a consistent approach to medical device regulation across EU member states.

Increasing Focus on Market Surveillance

A key priority for the Belgian regulator is market surveillance, which ensures that medical devices continue to comply with regulatory standards after they have entered the market.

Market surveillance activities may include:

• Monitoring device performance and safety reports

• Reviewing technical documentation

• Conducting inspections of manufacturers and distributors

• Investigating safety concerns related to medical devices

These measures help regulators identify potential risks early and ensure that corrective actions are implemented when necessary.

Responsibilities for Manufacturers

Manufacturers placing medical devices on the Belgian market must comply with the obligations set out under the EU MDR and IVDR frameworks.

These responsibilities include:

• Maintaining comprehensive technical documentation

• Implementing effective post-market surveillance systems

• Reporting serious incidents and field safety corrective actions

• Ensuring ongoing compliance with quality management requirements

  
  

For companies operating within the EU, maintaining strong regulatory processes is essential for ensuring both compliance and patient safety.

Belgium’s Strategic Role in European Life Sciences

Belgium is widely recognised as an important hub for the life sciences sector in Europe, with a strong ecosystem of pharmaceutical companies, medical technology firms, and research institutions.

The country’s regulatory framework supports innovation while ensuring that healthcare products meet high standards of safety and effectiveness.

As regulatory requirements continue to evolve under the EU MDR and IVDR frameworks, Belgium remains an active participant in shaping the European regulatory environment for medical technologies.

ARQon Perspective

Belgium’s continued focus on regulatory compliance and market surveillance reflects broader trends across the European medical device sector. Regulators are increasingly emphasising product lifecycle oversight, ensuring that medical technologies remain safe and effective throughout their time on the market.

For manufacturers operating in Europe, understanding national regulatory expectations within the EU framework remains critical for successful market access and long-term compliance.

At ARQon, we continue to monitor regulatory developments across global markets to support organisations navigating complex compliance landscapes and bringing safe, innovative medical technologies to patients worldwide.